Investors seeking the next obesity-like market opportunity will be closely watching developments related to treatments for Alzheimer’s disease in 2025.Most Read from BloombergWhat Robotaxis ...

NeurEYE uses AI and anonymized eye scans to assess dementia risk and brain health indicators, leveraging data from Scottish ...

New guidelines will help doctors identify patients with a common memory-loss syndrome that is often misdiagnosed as Alzheimer's disease in older adults. The diagnostic criteria for limbic-predominant ...

Jan. 15, 2025 — Regular aerobic exercise could significantly reduce disease markers associated with Alzheimer's, new research has found. The findings provide new hope in the battle against this ...

Scottish researchers are working on a new AI tool that could be used by high-street opticians to spot the early signs of dementia. Photographs taken of the retina at the back of the eye can give ...

Alzheimer's disease is a progressive neurodegenerative disease that impairs memory and cognitive judgment and is often accompanied by mood swings, disorientation and eventually delirium.

It is focusing on retinal diseases, with its most advanced programme AGTC-501 for X-linked retinitis pigmentosa (XLRP), which is in the phase 2/3 VISTA trial. AGTC-501 is vying to become the first ...

TauRx Pharma's effort to bring a tau-targeting drug for Alzheimer's disease (AD) to market has been a marathon, with a number of setbacks over the years, but the company reckons it may finally be ...

Photographs taken of the retina ... to Dementia UK it affects one in 14 people over the age of 65, and one in six people over the age of 80. Conditions such as Alzheimer's disease can lead to ...